Africa: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis At 2016 Digestive Disease Week (DDW) Annual Meeting
[PR Newswire] Osaka -Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the oral presentations of two data analyses: one evaluating the optimal position of vedolizumab in the ulcerative colitis (UC) treatment paradigm, and a second separate analysis assessing whether early vedolizumab trough levels were associated with subsequent drug efficacy. Findings were presented during the 2016 Digestive Disease Week (DDW) Annual Meeting in San Diego, California, and were included in a total of 13 Takeda-sponso
Conclusions: Data produced in this study do not encourage ganciclovir treatment for UC patients. However, studies included in this analysis were observational, and thus, inherited severe selection bias. We suggest randomized controlled studies be conducted to make firm recommendations in this context. PMID: 31718340 [PubMed - as supplied by publisher]
Authors: Khorshidi M, Djafarian K, Aghayei E, Shab-Bidar S Abstract Inflammatory bowel disease (IBD) is a chronic inflammatory disorder which affects the gastrointestinal tract. Many factors, such as genetics, stress, and dietary patterns have been related to the risk of this disease. Adherence to a prudent/healthy dietary pattern, due to its antioxidant and anti-inflammatory properties, help to reduce the risk of many chronic diseases such as IBD. The results from previous studies regarding the association between dietary patterns and risk of IBD, including Crohn's disease (CD) and ulcerative colitis (UC), are in...
ConclusionsTaking together, these results suggest that myricetin exhibits significant protective effects against UC and it could be used as a potential treatment for UC.
AbstractObjectiveIL23R plays an important role in the pathogenesis of inflammatory bowel disease (IBD). The IL23R rs11209026 and rs10889677 polymorphisms have been shown to be associated with the development of Crohn ’s disease (CD) and ulcerative colitis (UC). But the results were inconsistent and inconclusive. So, we aim to investigate the genetic association between rs11209026 and rs10889677 polymorphisms and UC and CD risk by a meta-analysis.MethodsLiterature search was conducted through PubMed, CNKI, and web of science databases. Pooled OR and 95% CI was used to assess the association between the allelic, domina...
AbstractBackgroundGolimumab is a new anti-TNF-alpha monoclonal antibody for patients with ulcerative colitis.AimsTo assess the short- and long-term effectiveness and safety of golimumab in daily clinical practice and to identify predictors of response.MethodsConsecutive patients treated with golimumab in 22 Italian centers were enrolled. Clinical, laboratory, and endoscopic data were prospectively collected before and during treatment. A subgroup of patients completed a questionnaire to assess personal satisfaction with a golimumab autoinjector system.ResultsA total of 196 patients were included. After 3 months, 130 ...
Phase III trials demonstrated effectiveness of tofacitinib, an oral Janus kinase inhibitor, to induce and maintain remission in patients with moderate-to-severe active ulcerative colitis (UC).
CONCLUSION: This study shows that IBD children present at diagnosis an increased frequency of circulating Tregs, probably as a compensative reaction to tissue inflammation. During the clinical remission, the Treg frequency diminishes, and concomitantly, their activation status increases. Notwithstanding, the high Treg density at diagnosis is not sufficient to counteract the inflammation in the childhood IBD. PMID: 31715619 [PubMed - as supplied by publisher]
Conditions: Irritable Bowel Syndrome; Ulcerative Colitis Intervention: Other: Osteopathy Sponsor: Clinique Paris-Bercy Not yet recruiting